Promising exploratory efficacy data were also published from another phase-Ia/Ib trial (KOMET-001) assessing the Menin inhibitor ziftomenib in heavily pretreated relapsed or refractory AML, which also led to the assignment of breakthrough designation status from the FDA [107]. The gene discussed is MEN1; the disease is acute myeloid leukemia.